Literature DB >> 30951815

Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway?

Xiang-Nan Yu1, Hong Chen2, Tao-Tao Liu1, Jian Wu3, Ji-Min Zhu4, Xi-Zhong Shen5.   

Abstract

The mechanistic target of rapamycin (mTOR) pathway coordinates organismal growth and homeostasis in response to growth factors, nutrients, and cellular energy stage. The pathway regulates several major cellular processes and is implicated in various pathological conditions, including hepatocellular carcinoma (HCC). This review summarizes recent advances of the mTOR pathway, highlights the potential of the mTOR pathway as a therapeutic target, and explores clinical trials targeting the mTOR pathway in HCC. Although the review focuses on the mTOR pathway involved in HCC, more comprehensive discussions (eg, developing a rational design for future trials targeting the mTOR pathway) are also applicable to other tumors.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cellular function; Hepatocellular carcinoma; Non-coding RNAs; The mTOR pathway; Therapeutic target

Mesh:

Substances:

Year:  2019        PMID: 30951815     DOI: 10.1016/j.bbcan.2019.03.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  9 in total

Review 1.  Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.

Authors:  Jun Gong; Jeremy Chuang; May Cho; Kyra Toomey; Andrew Hendifar; Daneng Li
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

2.  CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.

Authors:  Encheng Zhang; Siteng Chen; Heting Tang; Cheng Fei; Zhihao Yuan; Xingyu Mu; Yan Qin; Haixia Liu; Yu Fan; Mingyue Tan; Xiang Wang
Journal:  Cancer Sci       Date:  2021-11-16       Impact factor: 6.716

3.  Pre-mRNA processing factor 19 functions in DNA damage repair and radioresistance by modulating cyclin D1 in hepatocellular carcinoma.

Authors:  Xiang-Nan Yu; Guang-Cong Zhang; Hai-Ning Liu; Jin-Min Zhu; Tao-Tao Liu; Guang-Qi Song; Ling Dong; Jie Yin; Xi-Zhong Shen
Journal:  Mol Ther Nucleic Acids       Date:  2021-12-09       Impact factor: 8.886

4.  Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Dongyu Wu; Guangcong Zhang; Jiamei Ma; Hongfen Wu; Ju Xiong; Xiaoxi Huang; Yuanyuan Tian; Taozhi Deng; Xiangyang Han; Xiaoning Sun; Tian Xiang; Xiangnan Yu; Xuemei Jiang
Journal:  J Oncol       Date:  2021-10-08       Impact factor: 4.375

5.  UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.

Authors:  Zhan Shi; Runkun Liu; Qiliang Lu; Zhi Zeng; Yang Liu; Junjun Zhao; Xin Liu; Lijie Li; Hui Huang; Yingmin Yao; Dongsheng Huang; Qiuran Xu
Journal:  Int J Med Sci       Date:  2021-10-11       Impact factor: 3.738

6.  microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Bilegsaikhan Enkhnaran; Guang-Cong Zhang; Ning-Ping Zhang; Hai-Ning Liu; Hao Wu; Shi Xuan; Xiang-Nan Yu; Guang-Qi Song; Xi-Zhong Shen; Ji-Min Zhu; Xiu-Ping Liu; Tao-Tao Liu
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

7.  Cyclin B2 overexpression promotes tumour growth by regulating jagged 1 in hepatocellular carcinoma.

Authors:  Yening Xiao; Jiamei Ma; Chunliu Guo; Danni Liu; Jing Pan; Xiaoxi Huang
Journal:  Aging (Albany NY)       Date:  2022-03-29       Impact factor: 5.682

8.  AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma.

Authors:  Nan Geng; Yuanyuan Jin; Yurong Li; Shixuan Zhu; Han Bai
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

9.  MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.

Authors:  Guohua Lou; Liang Chen; Caixia Xia; Weina Wang; Jinjin Qi; Aichun Li; Liying Zhao; Zhi Chen; Min Zheng; Yanning Liu
Journal:  J Exp Clin Cancer Res       Date:  2020-01-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.